(FBIO) Fortress Biotech - Ratings and Ratios

Fortress Biotech, Inc. (NASDAQ:FBIO) is a biopharmaceutical company specializing in the development and commercialization of dermatology, pharmaceutical, and biotechnology products. Its product portfolio includes treatments for various dermatological conditions, such as hyperhidrosis, acne, and fungal infections. Key marketed products include Qbrexza, a medicated cloth for axillary hyperhidrosis; Accutane for severe acne; Amzeeq and Zilxi for acne vulgaris; Exelderm for fungal infections; and doxycycline formulations for acne and other indications. The company also focuses on developing late-stage candidates, including CUTX-101 for Menkes disease, Cosibelimab for metastatic cancers, and CAEL-101 for amyloidosis. Its pipeline extends to early-stage and preclinical candidates targeting gout, lymphoma, glioblastoma, and immunodeficiency disorders, leveraging technologies like CAR T, gene therapy, and oligonucleotide platforms. Fortress Biotech, rebranded from Coronado Biosciences in 2015, operates from Bay Harbor Islands, Florida.

The companys late-stage pipeline includes intravenous Tramadol for post-operative pain, Olafertinib for EGFR mutation-positive NSCLC, and Triplex vaccine for cytomegalovirus. Early-stage candidates encompass MB-106 for B-cell non-Hodgkin lymphoma, MB-101 for glioblastoma, and MB-117 for x-linked severe combined immunodeficiency. Preclinical efforts involve Mayo Clinics CAR T platform, AAV-ATP7A gene therapy, and CK-103 BET inhibitor. Fortress Biotechs strategic approach emphasizes a diversified pipeline addressing unmet medical needs across multiple therapeutic areas.

Ticker Symbol: FBIO Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Average Volume 20d: 275519 Last Price: 1.52 SMA 20: 1.64 SMA 50: 1.82 SMA 200: 1.84 ATR: 0.10

Market Cap: 46.86M USD P/E: 0.00 P/E Forward: 0.00 P/B: 2.05 P/S: 0.53 RoE: None

3-Month Forecast: Based on technical and fundamental data, FBIO may face headwinds due to its current price below the 20-day SMA of 1.64 and 50-day SMA of 1.82. The ATR of 0.10 suggests moderate volatility. However, the P/B ratio of 2.05 indicates the stock is trading near its book value, potentially signaling undervaluation. The companys diversified pipeline and focus on late-stage candidates could drive sentiment, but near-term price movement may remain range-bound between 1.40 and 1.80, influenced by clinical trial updates and broader market conditions.